Last reviewed · How we verify
CI 0.2% ropivacaine
CI 0.2% ropivacaine is a marketed anesthetic developed by the University Health Network in Toronto, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | CI 0.2% ropivacaine |
|---|---|
| Also known as | ropivacaine 0.2% Continuous infusion |
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Analgesic Efficacy of Continuous Infusion of Local Anaesthetic Versus Single-shot Injection Interscalene Block (NA)
- Catheter-based Peripheral Regional Anesthesia After Orthopedic Surgery to the Foot or Ankle (PHASE4)
- Catheter-based Peripheral Regional Anesthesia After Total Knee Arthroplasty (PHASE4)
- Local Anesthetic Automated Intermittent Administration vs. Continuous Infusion Via Femoral Nerve Block. (PHASE4)
- PIB Versus CI Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CI 0.2% ropivacaine CI brief — competitive landscape report
- CI 0.2% ropivacaine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI